IMC-S118AI
Phase 1Biologic
IMC-S118AI is one of 35 biologic programs targeting Type 1 Diabetes. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
79 competitors in Type 1 Diabetes
#DrugCompanyPhaseTrials
1Ozempic
Novo NordiskPhase 3
Stelara
Johnson & JohnsonPhase 3
Inpefa
LLexicon Pharmaceuticals
Phase 3
Tricor
JJagotec
Phase 3
Diamox
TevaPhase 2
Humira
NovartisPhase 2
Kerendia
BayerPhase 2
Teplizumab
SanofiPhase 3
Prolia
OOrganon and Co
Phase 2
Bacillus Calmette-Guérin
Bristol-Myers SquibbPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IMC-S118AI. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- IImmunocore Ltd